2024-11-23 - Analysis Report
## Eli Lilly and Co (LLY) Stock Analysis Report

**1. Performance Comparison and Outperformance:**

Eli Lilly and Co. (LLY) is a global pharmaceutical company engaged in the research, development, manufacturing, and marketing of pharmaceutical products.

The cumulative return for LLY is significantly higher than that of the S&P 500 (VOO).

| Metric             | LLY        | VOO        | Difference | Relative Outperformance |
|----------------------|-------------|-------------|-------------|--------------------------|
| Cumulative Return | 587.41%     | 127.58%     | 459.83%     | 68.58%                   |


The table below shows the Compound Annual Growth Rate (CAGR), Maximum Drawdown (MDD), Alpha, Beta, and Market Capitalization (Cap) for different periods.  LLY consistently exhibits high CAGR and positive alpha, indicating outperformance relative to the market (as represented by Beta).  However, it also experiences significant MDD, reflecting the inherent risk in the pharmaceutical sector.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|------|
| 2015-2017  | 30.4% | 16.1% | -8.0% | 0.8 | 80.2 |
| 2016-2018  | 50.8% | 16.1% | 18.5% | 0.7 | 109.8 |
| 2017-2019  | 89.5% | 14.6% | 37.8% | 0.7 | 124.8 |
| 2018-2020  | 113.2% | 20.8% | 65.8% | 0.7 | 160.3 |
| 2019-2021  | 154.6% | 20.8% | 54.6% | 0.7 | 262.2 |
| 2020-2022  | 190.4% | 20.8% | 166.8% | 0.7 | 347.3 |
| 2021-2023  | 266.0% | 18.4% | 231.1% | 0.5 | 553.4 |
| 2022-2024  | 183.6% | 23.9% | 153.5% | 0.6 | 711.9 |


**2. Recent Price Movement:**

| Metric             | Value     |
|----------------------|-------------|
| Closing Price       | 747.79    |
| 5-Day Moving Average | 741.61    |
| 20-Day Moving Average| 799.84    |
| 60-Day Moving Average| 873.92    |

The stock price is currently below its 5, 20, and 60-day moving averages, suggesting a downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI (37.12):**  Suggests the stock is in oversold territory, potentially indicating a bounce back.
* **PPO (-0.56):** Negative PPO suggests bearish momentum.
* **Delta_Previous_Relative_Divergence (-20.19):** Shows a recent decrease in relative outperformance.
* **Expected Return (169.79%):**  This represents a significant projected long-term (2+ years) outperformance compared to the S&P 500, assuming continued strong performance.  This high number should be viewed with caution, as it relies on past performance which may not be indicative of future results. The current price of 747.79, being below moving averages, does not suggest immediate  a significant price bounce, despite the positive long-term expectation.


**4. Recent Financial Performance:**

| Date       | EPS     | Revenue      |
|------------|---------|---------------|
| 2024-10-30 | 1.08    | $11.44 B     |
| 2024-08-08 | 3.29    | $11.30 B     |
| 2024-04-30 | 2.49    | $8.77 B      |
| 2023-11-02 | -0.06   | $9.50 B      |
| 2024-10-30 | -0.06   | $9.50 B      |


Note:  There appears to be a duplicate entry for October 30th, 2024.  Clarification is needed on the accurate data. The recent earnings show fluctuating performance,  requiring further analysis to determine underlying trends and whether the October 30th, 2024 data accurately reflects the companyâ€™s performance.  Comparison to analyst expectations is crucial for a complete evaluation.


**6. Financial Information:**


**1) Revenue and Profitability:**

| Quarter     | Revenue     | Profit Margin |
|-------------|-------------|---------------|
| 2024-09-30  | $11.44B    | 81.02%        |
| 2024-06-30  | $11.30B    | 80.80%        |
| 2024-03-31  | $8.77B     | 80.91%        |
| 2023-12-31  | $9.35B     | 80.88%        |
| 2023-09-30  | $9.50B     | 80.42%        |

The company shows consistent high profit margins.  Revenue fluctuates, indicating potential seasonality or other factors influencing sales.


**2) Capital and Profitability:**

| Quarter     | Equity      | ROE           |
|-------------|-------------|---------------|
| 2024-09-30  | $14.24B    | 6.81%         |
| 2024-06-30  | $13.56B    | 21.88%        |
| 2024-03-31  | $12.81B    | 17.51%        |
| 2023-12-31  | $10.77B    | 20.33%        |
| 2023-09-30  | $11.22B    | -0.51%        |

ROE fluctuates significantly,  requiring further investigation into the reasons behind these variations.


**7. News and Recent Issues:**

*(This section requires access to real-time news sources such as Shacknews, FINBOLD, etc.  Please provide specific news articles or links for a comprehensive analysis.)*  A review of recent news (within the past two days) covering earnings announcements, analyst opinions, and market outlooks is essential for completing this section.

**8. Overall Analysis:**

LLY has demonstrated significant outperformance relative to the S&P 500 over various periods.  However, this outperformance comes with higher risk, as evidenced by the MDD figures.  While the current price is below key moving averages, suggesting a short-term bearish trend, the high projected long-term expected return and potentially oversold RSI signal  potential for future growth.  The recent financial performance shows mixed results, requiring a more in-depth analysis incorporating analyst estimates and news regarding recent developments.  Further investigation into the reasons behind fluctuating ROE and clarifying discrepancies in the reported financial data are crucial before making any investment decision.  A thorough review of recent news and analyst opinions is necessary to gain a complete picture of the current market outlook and assess the validity of the high expected return.

**9. Disclaimer:** This report is for informational purposes only and should not be considered investment advice.  Conduct thorough due diligence and consult with a qualified financial advisor before making any investment decisions.
